rss

This article has a correction

Please see: Ann Rheum Dis 2010;70:240

Ann Rheum Dis 69:1097-1102 doi:10.1136/ard.2009.109850
  • Letter

Successful use of rituximab in a patient with Churg–Strauss syndrome and refractory central nervous system involvement

  1. Andrea Rubbert-Roth1
  1. 1University Hospital of Cologne, Department of Internal Medicine I, Cologne, Germany
  2. 2University Hospital of Cologne, Department of Radiology, Cologne, Germany
  3. 3Holy-Ghost Hospital of Cologne, Cologne, Germany
  1. Correspondence to Dr Jasemine Saech, University Hospital of Cologne, Department of Internal Medicine I, Kerpenerstrasse 62, 50924 Cologne, Germany; jasemine.saech{at}uk-koeln.de
  • Accepted 1 September 2009
  • Published Online First 9 September 2009

The major clinical manifestations of Churg–Strauss syndrome (CSS) include asthma, hypereosinophilia and the extrapulmonary manifestation of systemic vasculitis.1 The involvement of the central nervous system (CNS) is less common (<10%), with significant morbidity and mortality in affected patients.2 Glucocorticoids combined with cyclophosphamide represent the treatment of choice in patients with severe involvement of the heart, nervous system or kidney.3 In the case of intolerance to cyclophosphamide, plasma exchange, interferon and mycophenolate mofetil (MMF) have been suggested as alternatives.4 A few case reports on the use of rituximab in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis and CSS are available5,,7; however, none reported on patients with …